[
    [
        {
            "time": "2023-10-01",
            "original_text": "Here is What Hedge Funds Think About Eli Lilly and Company (LLY)",
            "features": {
                "keywords": [
                    "Hedge Funds",
                    "Eli Lilly",
                    "LLY"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Here is What Hedge Funds Think About Eli Lilly and Company (LLY)",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "10 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors",
            "features": {
                "keywords": [
                    "Pharmaceutical Stocks",
                    "Buy",
                    "Brandon Haley",
                    "Holocene Advisors"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "10 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study",
            "features": {
                "keywords": [
                    "Biohaven",
                    "BHVN",
                    "Intranasal Migraine",
                    "Therapy",
                    "Goal",
                    "Study"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19",
            "features": {
                "keywords": [
                    "Roche",
                    "RHHBY",
                    "Actemra",
                    "CHMP",
                    "Recommendation",
                    "COVID-19"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]